Literature DB >> 21876047

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

A Espinel-Ingroff1, M Cuenca-Estrella, A Fothergill, J Fuller, M Ghannoum, E Johnson, T Pelaez, M A Pfaller, J Turnidge.   

Abstract

Although clinical breakpoints have not been established for mold testing, epidemiological cutoff values (ECVs) are available for Aspergillus spp. versus the triazoles and caspofungin. Wild-type (WT) MIC distributions (organisms in a species-drug combination with no acquired resistance mechanisms) were defined in order to establish ECVs for six Aspergillus spp. and amphotericin B. Two sets (CLSI/EUCAST broth microdilution) of available MICs were evaluated: those for A. fumigatus (3,988/833), A. flavus (793/194), A. nidulans (184/69), A. niger (673/140), A. terreus (545/266), and A. versicolor (135/22). Three sets of data were analyzed: (i) CLSI data gathered in eight independent laboratories in Canada, Europe, and the United States; (ii) EUCAST data from a single laboratory; and (iii) the combined CLSI and EUCAST data. ECVs, expressed in μg/ml, that captured 95%, 97.5%, and 99% of the modeled wild-type population (CLSI and combined data) were as follows: for A. fumigatus, 2, 2, and 4; for A. flavus, 2, 4, and 4; for A. nidulans, 4, 4, and 4; for A. niger, 2, 2, and 2; for A. terreus, 4, 4, and 8; and for A. versicolor, 2, 2, and 2. Similar to the case for the triazoles and caspofungin, amphotericin B ECVs may aid in the detection of strains with acquired mechanisms of resistance to this agent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21876047      PMCID: PMC3195003          DOI: 10.1128/AAC.00686-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Authors:  J Turnidge; G Kahlmeter; G Kronvall
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

Review 3.  Mechanisms and clinical impact of antifungal drug resistance.

Authors:  H Vanden Bossche; D W Warnock; B Dupont; D Kerridge; S Sen Gupta; L Improvisi; P Marichal; F C Odds; F Provost; O Ronin
Journal:  J Med Vet Mycol       Date:  1994

4.  Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; A Fothergill; J Fuller; E Johnson; T Pelaez; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

5.  Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus.

Authors:  K Seo; H Akiyoshi; Y Ohnishi
Journal:  Microbiol Immunol       Date:  1999       Impact factor: 1.955

6.  Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp.

Authors:  Alicia Gomez-Lopez; Amel Aberkane; Eva Petrikkou; Emilia Mellado; Juan Luis Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus.

Authors:  S Arunmozhi Balajee; Jennifer L Gribskov; Edward Hanley; David Nickle; Kieren A Marr
Journal:  Eukaryot Cell       Date:  2005-03

8.  Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

Authors:  Thomas J Walsh; Vidmantas Petraitis; Ruta Petraitiene; Aida Field-Ridley; Deanna Sutton; Mahmoud Ghannoum; Tin Sein; Robert Schaufele; Joanne Peter; John Bacher; Heather Casler; Derek Armstrong; Anna Espinel-Ingroff; Michael G Rinaldi; Caron A Lyman
Journal:  J Infect Dis       Date:  2003-07-09       Impact factor: 5.226

Review 9.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

10.  Amphotericin B-induced oxidative damage and killing of Candida albicans.

Authors:  M L Sokol-Anderson; J Brajtburg; G Medoff
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

View more
  57 in total

1.  Aspergillus terreus infection in a sutureless self-sealing incision made during cataract surgery.

Authors:  Elif Erdem; Hazal Kandemir; Sevtap Arıkan-Akdağlı; Ebru Esen; Arbil Açıkalın; Meltem Yağmur; Macit İlkit
Journal:  Mycopathologia       Date:  2014-11-02       Impact factor: 2.574

2.  Emergence of TR46/Y121F/T289A in an Aspergillus fumigatus isolate from a Chinese patient.

Authors:  Yong Chen; Huan Wang; Zhongyi Lu; Peng Li; Qing Zhang; Tianye Jia; Jingya Zhao; Shuguang Tian; Xuelin Han; Fangyan Chen; Changjian Zhang; Xiaodong Jia; Liuyu Huang; Fen Qu; Li Han
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

3.  In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus.

Authors:  Maria Siopi; Johan W Mouton; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

4.  Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad Taghi Hedayati; Saham Ansari; Saeed Mahdavi Omran; Sasan Saber; Haleh Rafati; Jan Zoll; Henrich A van der Lee; Willem J G Melchers; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 5.  Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard.

Authors:  Shawn R Lockhart; Mahmoud A Ghannoum; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2017-02-15       Impact factor: 5.948

6.  Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease.

Authors:  S Seyedmousavi; Y C Chang; D Law; M Birch; J H Rex; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

7.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07

8.  In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

9.  Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Rafal Al-Saigh; Maria Siopi; Nikolaos Siafakas; Aristea Velegraki; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

10.  Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method.

Authors:  A Espinel-Ingroff; A Chowdhary; G M Gonzalez; C Lass-Flörl; E Martin-Mazuelos; J Meis; T Peláez; M A Pfaller; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.